Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin Combo in Refractory Multiple Myeloma
NCT03117361Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- May 2017
- Primary completion
- Jul 2018
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in multiple myeloma (MM), sponsored by PharmaMar. Primary endpoints: Overall Response Rate up to 100 weeks and Overall Response up to 100 weeks. Started May 2017; status: terminated.
02
Drugs
plitidepsin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03117361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117361.